Jan 27th, 2023, 15:38
|
只看该作者 #7322 | |
|
我是轮子谁也不怕 我
 
注册日期: Oct 2009
帖子: 7,797
积分:3
精华:1
声望: 2647981
  |
引用:
tsla，avgo，tmus，这几个不在碗里 由于没有短线思维，所以不一定合用，这不意味它们没有短线机会 万一套住，这些捂着应该不会太差，偶可以不负责任的说 |
|
|
|
|
感谢 西部山人监督者宋祖德 此篇文章之用户： |
China_Soul (Jan 27th, 2023) |
|
Jan 27th, 2023, 16:13
|
只看该作者 #7325 | |
|
帅哥他爸
 
注册日期: Jul 2004
住址: BC
帖子: 6,359
积分:49
精华:17
声望: 6319487
|
引用:
TSLA基本打平，近期没有再入过。HD，costco都买过，四平八稳的，差不多就放了，最近听说HD把客户的email 透露给fb发定向广告了，闹大了应该可以捡点便宜。 其他不熟，我今晚研究研究。 |
|
|
|
|
|
Jan 30th, 2023, 00:17
|
只看该作者 #7337 |
|
Senior Member
 
注册日期: Jun 2006
帖子: 4,513
声望: 1177764
|
与辉瑞有关联的一个同性恋者声称辉瑞功能化病毒后，视频一下子有2000多万流量。 辉瑞发表了声明，没主动进行功能化增益研究，但是在药物研究中一定条件下进行了病毒功能工程干预。 现在是谈病毒功能工程干预就是个禁区，民众不接受，似乎在医药科学界很平常。 “Pfizer Responds to Research Claims Friday, January 27, 2023 - 08:00pm Share link New York, N.Y., January 27, 2023 – Allegations have recently been made related to gain of function and directed evolution research at Pfizer and the company would like to set the record straight. In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research. Working with collaborators, we have conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. This work is undertaken once a new variant of concern has been identified by public health authorities. This research provides a way for us to rapidly assess the ability of an existing vaccine to induce antibodies that neutralize a newly identified variant of concern. We then make this data available through peer reviewed scientific journals and use it as one of the steps to determine whether a vaccine update is required. In addition, to meet U.S. and global regulatory requirements for our oral treatment, PAXLOVID™, Pfizer undertakes in vitro work (e.g., in a laboratory culture dish) to identify potential resistance mutations to nirmatrelvir, one of PAXLOVID’s two components. With a naturally evolving virus, it is important to routinely assess the activity of an antiviral. Most of this work is conducted using computer simulations or mutations of the main protease–a non-infectious part of the virus. In a limited number of cases when a full virus does not contain any known gain of function mutations, such virus may be engineered to enable the assessment of antiviral activity in cells. In addition, in vitro resistance selection experiments are undertaken in cells incubated with SARS-CoV-2 and nirmatrelvir in our secure Biosafety level 3 (BSL3) laboratory to assess whether the main protease can mutate to yield resistant strains of the virus. It is important to note that these studies are required by U.S. and global regulators for all antiviral products and are carried out by many companies and academic institutions in the U.S. and around the world. Fact-based information rooted in sound science is vitally important to overcoming the COVID-19 pandemic and Pfizer remains committed to transparency and helping alleviate the devastating burden of this disease.” |
|
|
|
 |
|
|
请尊重文章原创者，转帖请注明来源及原作者。
凡是本站用户自行发布的任何信息，皆不代表本站的立场，
华枫网站不确保各类信息的正确性和可靠性，也不承担由此而导致的任何直接或间接损失以及任何法律责任。 |
